CALL - SPRINTER OPEN END - ROCHE GS Share Price

Certificat

DE000VU42DT5

Market Closed - Deutsche Boerse AG 11:23:45 14/06/2024 pm IST
4.3 EUR +3.61% Intraday chart for CALL - SPRINTER OPEN END - ROCHE GS
Current month+66.67%
1 month+117.17%
Date Price Change
14/24/14 4.3 +3.61%
13/24/13 4.15 +8.07%
12/24/12 3.84 +4.63%
11/24/11 3.67 +4.86%
10/24/10 3.5 -6.17%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 11:23 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU42DT
ISINDE000VU42DT5
Date issued 20/03/2023
Strike 205.5 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 6.52
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 9.56
Lowest since issue 0.99

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus